TEMPO: A Phase 2, Randomized, Open-Label, 2-Arm Study Comparing 2 Intermittent Dosing Schedules of Duvelisib in Subjects with Indolent Non Hodgkin Lymphoma (iNHL)
- Resource Type
- Abstract
- Source
- In
Blood 23 November 2021 138 Supplement 1:3545-3545 - Subject
- Language
- ISSN
- 0006-4971